Compare Northrop Grumman Corporation (NOC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Northrop Grumman Corporation trades at $480.06 (market cap $68.83B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Northrop Grumman Corporation is far larger — about 4.1× Zimmer Biomet Holdings Inc's market cap, and Northrop Grumman Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NOC | ZBH | |
|---|---|---|
Market Cap | $68.83B | $16.95B |
Volume | 1,081,989 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $768.02 | $103.98 |
52-Week Low | $473.46 | $79.58 |
Typical Hold Time | 81 Days | 89 Days |
Enterprise Value | $82.81B | $24.02B |
Dividend Yield | 2.04% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $480.85, up 1.56% with recent earnings beats but faces technical bearish signals. The company maintains strong fundamentals with $41.95B revenue, 10.48% net margin, and attractive valuation at 15.4 P/E. Recent news highlights both contract wins and competitive losses, including Boeing's $20B Navy fighter award.
Outlook remains positive with analyst consensus at $600.62 target (25% upside) and 54% buy ratings. Key risks include defense contract volatility and competitive pressures, while strong backlog ($104.7B) and dividend growth support long-term value. The stock offers defensive exposure to elevated defense spending cycles.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
